Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 23, Issue 18, 2005, Pages 4070-4078

  Wierda, William ^a   O'Brien, Susan ^a   Wen, Sijin ^a   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   Thomas, Deborah ^a   Do, Kim Anh ^a   Cortes, Jorge ^a   Koller, Charles ^a   Beran, Miloslav ^a   Ferrajoli, Alessandra ^a   Giles, Francis ^a   Lerner, Susan ^a   Albitar, Maher ^a   Kantarjian, Hagop ^a   Keating, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUDARABINE; ONDANSETRON; PARACETAMOL; RITUXIMAB; VALACICLOVIR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; BRONCHITIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELLULITIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HYPOTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RASH; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; CHI SQUARE DISTRIBUTION; DISEASE COURSE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIDARABINE;

EID: 23044501404     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.12.516     Document Type: Article

References (22)

1. Yamauchi T, Nowak BJ, Keating MJ, et al: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7:3580-3589, 2001
2. O'Brien SM, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001
3. Hallek M, Schmitt B, Wilhelm M, et al: Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocyte leukaemia (CLL): Results of a phase II study of the German CLL Study Group. Br J Haematol 114:342-348, 2001
4. Di Gaetano N, Xiao Y, Erba E, et al: Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114:800-809, 2001
5. Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709-723, 2001
6. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
7. Cheson BD, Bennett JM, Rai KR, et al: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am J Hematol 29:152-163, 1988
8. Slavickova A, Ullmannova V, Klener P: Optimized multiplex IgH/ras PCR: A tool for quantitative monitoring of B-lymphoproliferative disorders. Biotechniques 28:716-718, 720-721, 2000
9. Albitar M, Wu WI, Feltz E, et al: Simplified reverse dot blot analyses for detecting of ras oncogene mutations. Mol Diagn 2:169-176, 1997
10. Schultze JL, Donovan JW, Gribben JG: Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. J Mol Med 77:259-265, 1999
11. Bryant J, Day R: Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372-1383, 1995
12. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
13. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
14. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
15. Cox DR, Snell EJ: Analysis of Binary Data (ed 2). London, United Kingdom, Chapman and Hall, 1989
16. Rai KR: A critical analysis of staging in CLL, in Gale RP, Rai KR (eds): Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York, NY, Alan R. Liss, 1987, pp 253
17. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74: 19-25, 1989
18. O'Brien S, Kantarjian H, Beran M, et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695-1700, 1993
19. Fenchel K, Bergmann L, Wijermans P, et al: Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma 18:485-492, 1995
20. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99:3554-3561, 2002
21. Rai KR, Freter CE, Mercier RJ, et al: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20:3891-3897, 2002
22. Bosch F, Ferrer A, Lopez-Guillermo A, et al: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 119:976-984, 2002